Informa TechTarget to Announce 2025 First Quarter Financial Results on July 1, 2025
The Company's Chief Executive Officer, Gary Nugent, and Chief Financial Officer, Dan Noreck, will host a live conference call and webcast at 5:00 p.m. Eastern Time on that day to discuss the Company's financial results and outlook.
The Q1 2025 financial results will be available prior to the conference call and webcast on the investor relations section of the Company's website at https://investor.informatechtarget.com.
Conference Call Dial-In Information:
United States (Toll Free): 1-833-470-1428
United States: 1-404-975-4839
United Kingdom (Toll Free): +44 808 189 6484
United Kingdom: +44 20 8068 2558
Global Dial-in Numbers
Access code: 557186
Please access the call at least 10 minutes prior to the time the conference is set to begin.
Please ask to be joined into the Informa TechTarget call.
Conference Call Webcast Information:
This webcast can be accessed via Informa TechTarget's website at https://investor.informatechtarget.com/
Conference Call Replay Information:
A replay of the conference call will be available via telephone beginning one (1) hour after the conference call through July 31, 2025 at 11:59 p.m. ET. To hear the replay:
United States (Toll Free): 1-866-813-9403
United States: 1-929-458-6194
Access Code: 670569
A web version will also be available for replay during the same period on Informa TechTarget's website at https://investor.informatechtarget.com/
About Informa TechTarget
TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI.
With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market.
Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients:
Trusted information that shapes the industry and informs investment
Intelligence and advice that guides and influences strategy
Advertising that grows reputation and establishes thought leadership
Custom content that engages and prompts action
Intent and demand generation that more precisely targets and converts
Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit informatechtarget.com and follow us on LinkedIn.
© 2025 TechTarget, Inc. All rights reserved. All trademarks are the property of their respective owners.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 minutes ago
- Business Wire
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity contract entrusted to Kepler Cheuvreux. On 15 December 2017 Sensorion entered into a Liquidity Contract with Kepler Cheuvreux, modified by amendments dated 7 December 2018 and 15 July 2022 (the " Contract"). This Contract aims to promote the liquidity of the Shares of Sensorion on Euronext Paris. On 14 August 2025, in accordance with Article 4 of AMF Decision No. 2021-01 of 22 June 2021 renewing the establishment of liquidity contracts on equity securities as an accepted market practice, Sensorion increased the resources allocated to the liquidity contract by €60,000. Following this increase in resources, as of 14 August 2025, the following assets appear on the liquidity account: - 206,211 Sensorion Ordinary Shares - €66,965.21 About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Business Insider
15 minutes ago
- Business Insider
Cantor Fitzgerald Reaffirms Their Buy Rating on Kimball Electronics (KE)
Cantor Fitzgerald analyst Derek Soderberg maintained a Buy rating on Kimball Electronics today and set a price target of $27.00. The company's shares closed today at $24.71. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Soderberg is an analyst with an average return of -0.5% and a 42.04% success rate. In addition to Cantor Fitzgerald, Kimball Electronics also received a Buy from Financial's Mike Crawford in a report issued today. However, on August 2, TR | OpenAI – 4o downgraded Kimball Electronics (NASDAQ: KE) to a Hold. The company has a one-year high of $21.52 and a one-year low of $12.41. Currently, Kimball Electronics has an average volume of 150.5K.
Business Insider
16 minutes ago
- Business Insider
NICE (NICE) Receives a Buy from Northland Securities
Northland Securities analyst Michael Latimore reiterated a Buy rating on NICE today and set a price target of $250.00. The company's shares closed today at $127.85. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Latimore covers the Technology sector, focusing on stocks such as NICE, SoundHound AI, Inc Class A, and Rekor Systems. According to TipRanks, Latimore has an average return of 7.6% and a 44.29% success rate on recommended stocks. In addition to Northland Securities, NICE also received a Buy from Rosenblatt Securities's Catharine Trebnick in a report issued today. However, on the same day, D.A. Davidson maintained a Hold rating on NICE (NASDAQ: NICE). Based on NICE's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $700.19 million and a net profit of $129.29 million. In comparison, last year the company earned a revenue of $659.31 million and had a net profit of $106.37 million
